On the public citation graph

Rare diseases, orphan drugs and their regulation: questions and misconceptions

0 signed · 182 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.healthpol.2009.12.001openalex-snapshot
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
inferredcites →https://doi.org/10.1038/nrd3078openalex-snapshot
How to improve R&D productivity: the pharmaceutical industry's grand challenge
inferredcites →https://doi.org/10.1038/nrd3079openalex-snapshot
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
inferredcites →https://doi.org/10.1056/nejmp058317openalex-snapshot
Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases
inferredcites →https://doi.org/10.1111/j.1365-2125.2009.03369.xopenalex-snapshot
Orphan drug development is not taking off

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4781319openalex-extracted
Clinical Trial Evidence Supporting Fda Approval of Orphan Products between 2017 to 2023
inferred← citeshttps://doi.org/10.1002/9781119097440.ch2openalex-snapshot
REGULATION OF HUMAN PHARMACEUTICAL SAFETY
inferred← citeshttps://doi.org/10.1002/9781119755883.ch2openalex-snapshot
REGULATION OF HUMAN PHARMACEUTICAL SAFETY: ROUTES TO HUMAN USE AND MARKET
inferred← citeshttps://doi.org/10.1002/btpr.2538openalex-snapshot
High yield process for the production of active human α‐galactosidase a in CHO‐K1 cells through lentivirus transgenesis
inferred← citeshttps://doi.org/10.1002/cmdc.202300641openalex-snapshot
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective
inferred← citeshttps://doi.org/10.1002/ddr.21005openalex-snapshot
Orphan Drugs for Rare Diseases: Grounds for Special Status
inferred← citeshttps://doi.org/10.1002/jcph.1053openalex-snapshot
Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children
inferred← citeshttps://doi.org/10.1002/jcph.2167openalex-snapshot
Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases
inferred← citeshttps://doi.org/10.1002/jcph.599openalex-snapshot
A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
inferred← citeshttps://doi.org/10.1007/978-1-4471-2401-6_2openalex-snapshot
The Challenges of Clinical Research in Orphan Diseases
inferred← citeshttps://doi.org/10.1007/978-3-030-78605-2_23openalex-snapshot
Integrated Life Cycle Management for Rare and Orphan Products
inferred← citeshttps://doi.org/10.1007/978-3-031-12950-6_2openalex-snapshot
Challenges of Clinical Research in Orphan Diseases
inferred← citeshttps://doi.org/10.1007/978-3-032-04060-2_5openalex-snapshot
Regulatory Exclusivities
inferred← citeshttps://doi.org/10.1007/978-3-032-23626-5_13openalex-snapshot
Accelerating Drug Discovery and Development: Harnessing AI for Enhanced Efficiency and Speed
inferred← citeshttps://doi.org/10.1007/978-3-642-21992-4_3openalex-snapshot
Orphan-Arzneimittel
inferred← citeshttps://doi.org/10.1007/978-94-017-9214-1_3openalex-snapshot
Emerging Technologies for Gene Identification in Rare Diseases
inferred← citeshttps://doi.org/10.1007/s10389-023-01899-0openalex-snapshot
The importance of the policy framework on orphan drug accessibility
inferred← citeshttps://doi.org/10.1007/s10637-022-01227-5openalex-snapshot
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
inferred← citeshttps://doi.org/10.1007/s10728-020-00394-xopenalex-snapshot
When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing
inferred← citeshttps://doi.org/10.1007/s11030-024-10810-2openalex-snapshot
Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement
inferred← citeshttps://doi.org/10.1007/s11192-019-03129-5openalex-snapshot
Comparative analysis of correlations of research and development indicators for rare diseases among Japan, the US, and Europe
inferred← citeshttps://doi.org/10.1007/s11910-014-0442-zopenalex-snapshot
The Role of Brain Tumor Advocacy Groups
inferred← citeshttps://doi.org/10.1007/s40258-023-00832-6openalex-snapshot
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
inferred← citeshttps://doi.org/10.1007/s40265-017-0788-zopenalex-snapshot
Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases
inferred← citeshttps://doi.org/10.1007/s40265-018-0882-xopenalex-snapshot
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges
inferred← citeshttps://doi.org/10.1007/s40273-015-0340-5openalex-snapshot
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation
inferred← citeshttps://doi.org/10.1007/s43441-025-00833-8openalex-snapshot
Insights into Support Systems for Orphan Drug Development: A Comparative Study
inferred← citeshttps://doi.org/10.1016/b978-0-12-816125-8.00003-1openalex-snapshot
In Silico Drug Design Methods for Drug Repurposing
inferred← citeshttps://doi.org/10.1016/b978-0-12-816125-8.00015-8openalex-snapshot
Application of In Silico Drug Repurposing in Infectious Diseases
inferred← citeshttps://doi.org/10.1016/b978-0-443-28942-2.00005-3openalex-snapshot
Application of nanotechnology in lysosomal storage diseases
inferred← citeshttps://doi.org/10.1016/j.addr.2022.114531openalex-snapshot
Liposomal formulations for treating lysosomal storage disorders
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.05.020openalex-snapshot
Carbohydrate-based drugs launched during 2000−2021
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.08.004openalex-snapshot
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
inferred← citeshttps://doi.org/10.1016/j.bbrc.2014.08.139openalex-snapshot
Widespread genome transcription: New possibilities for RNA therapies
inferred← citeshttps://doi.org/10.1016/j.cmpb.2017.09.003openalex-snapshot
Drug-target interaction prediction: A Bayesian ranking approach
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2021.104856openalex-snapshot
Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing
inferred← citeshttps://doi.org/10.1016/j.ddstr.2011.10.003openalex-snapshot
Orphan/rare drug discovery through drug repositioning
inferred← citeshttps://doi.org/10.1016/j.drudis.2011.10.004openalex-snapshot
Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives
inferred← citeshttps://doi.org/10.1016/j.drudis.2011.10.027openalex-snapshot
Determinants for successful marketing authorisation of orphan medicinal products in the EU
inferred← citeshttps://doi.org/10.1016/j.drudis.2012.02.005openalex-snapshot
Orphan drug development: an economically viable strategy for biopharma R&D
inferred← citeshttps://doi.org/10.1016/j.drudis.2012.08.009openalex-snapshot
Orphan drugs: the regulatory environment
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.06.012openalex-snapshot
EU marketing authorization review of orphan and non-orphan drugs does not differ
inferred← citeshttps://doi.org/10.1016/j.drudis.2016.06.014openalex-snapshot
Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence
inferred← citeshttps://doi.org/10.1016/j.drudis.2017.09.007openalex-snapshot
Uncovering novel repositioning opportunities using the Open Targets platform
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.01.005openalex-snapshot
Orphan drugs: major development challenges at the clinical stage
inferred← citeshttps://doi.org/10.1016/j.drudis.2024.104102openalex-snapshot
Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023
inferred← citeshttps://doi.org/10.1016/j.healthpol.2012.08.023openalex-snapshot
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
inferred← citeshttps://doi.org/10.1016/j.inoche.2022.109281openalex-snapshot
A strategy toward therapeutic improvement of electric field-sensitive gemcitabine prodrugs in 2D metal–organic frameworks in view of their structure and interactions
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2021.102522openalex-snapshot
R&D and market size: Who benefits from orphan drug legislation?
inferred← citeshttps://doi.org/10.1016/j.jpeds.2020.01.063openalex-snapshot
Geographic and Specialty Access Disparities in US Pediatric Leukodystrophy Diagnosis
inferred← citeshttps://doi.org/10.1016/j.rare.2026.100119openalex-snapshot
Qualitative needs assessment of financial impact on caregivers of children living with rare diseases
inferred← citeshttps://doi.org/10.1016/j.rmr.2014.10.725openalex-snapshot
Maladies pulmonaires rares : de l’adoption des maladies orphelines à la structuration de la filière de soins
inferred← citeshttps://doi.org/10.1016/j.techfore.2021.120960openalex-snapshot
Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada
inferred← citeshttps://doi.org/10.1016/j.vhri.2022.10.008openalex-snapshot
Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey
inferred← citeshttps://doi.org/10.1016/s2213-2600(13)70085-7openalex-snapshot
Rare lung disease and orphan drug development
inferred← citeshttps://doi.org/10.1017/s0266462317000915openalex-snapshot
EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE
inferred← citeshttps://doi.org/10.1038/gt.2017.79openalex-snapshot
Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
inferred← citeshttps://doi.org/10.1038/nm.3193openalex-snapshot
Progress toward treatments for synaptic defects in autism
inferred← citeshttps://doi.org/10.1038/nrd3595openalex-snapshot
Clinical pharmacology as a cornerstone of orphan drug development
inferred← citeshttps://doi.org/10.1038/nrd3654openalex-snapshot
Rare diseases and orphan drugs
inferred← citeshttps://doi.org/10.1038/s41409-026-02839-8openalex-snapshot
Bringing the rare into sight: applications of haploidentical stem cell transplantation in the treatment of rare diseases
inferred← citeshttps://doi.org/10.1038/s41526-022-00224-5openalex-snapshot
Rare diseases and space health: optimizing synergies from scientific questions to care
inferred← citeshttps://doi.org/10.1038/s41573-019-0049-9openalex-snapshot
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
inferred← citeshttps://doi.org/10.1039/9781782624202-00003openalex-snapshot
Definitions, History and Regulatory Framework for Rare Diseases and Orphan Drugs
inferred← citeshttps://doi.org/10.1039/9781782624202-00083openalex-snapshot
Treating Rare Diseases: Business Model for Orphan Drug Development
inferred← citeshttps://doi.org/10.1055/s-0032-1309876openalex-snapshot
Seltene Erkrankungen in der Pneumologie und damit verbundene Herausforderungen
inferred← citeshttps://doi.org/10.1080/01459740.2019.1573229openalex-snapshot
Paces of Costly Care: Rare Disease Drug Access in Canada
inferred← citeshttps://doi.org/10.1080/21678421.2024.2400522openalex-snapshot
A scoping review of the role of managed entry agreements in upcoming drugs for amyotrophic lateral sclerosis: learning from the case of spinal muscular atrophy
inferred← citeshttps://doi.org/10.1080/21678707.2016.1180244openalex-snapshot
Measures to combat rare diseases and promote orphan drug development in Japan: government-funded special biomedical research programs to enhance basic and applied research
inferred← citeshttps://doi.org/10.1093/bib/bbr011openalex-snapshot
Old friends in new guise: repositioning of known drugs with structural bioinformatics
inferred← citeshttps://doi.org/10.1093/med/9780198746690.003.0225openalex-snapshot
The inborn errors of metabolism: General aspects
inferred← citeshttps://doi.org/10.1111/apce.12341openalex-snapshot
Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly
inferred← citeshttps://doi.org/10.1111/cts.12500openalex-snapshot
Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective
inferred← citeshttps://doi.org/10.1111/cts.12501openalex-snapshot
Progress in Rare Diseases Research 2010–2016: An IRDiRC Perspective
inferred← citeshttps://doi.org/10.1111/iep.12478openalex-snapshot
Clinical applications of gene therapy for rare diseases: A review
inferred← citeshttps://doi.org/10.1136/bmjopen-2025-108748openalex-snapshot
Clinical benefit, price and epidemiology of orphan drugs approved in China: a cross-sectional analysis of orphan drug policy (ODP) in China
inferred← citeshttps://doi.org/10.1136/medethics-2011-100204openalex-snapshot
Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia
inferred← citeshttps://doi.org/10.1159/000183178openalex-snapshot
Histochemical Detection of Ischemia-Like Alterations Induced in Kidney Tissue in vitro – Different Sensitivity to Oxidant Stress of Glomerular ENTPD1 versus E5NT
inferred← citeshttps://doi.org/10.1159/000362359openalex-snapshot
Personalized Medicine, Availability, and Group Disparity: An Inquiry into How Physicians Perceive and Rate the Elements and Barriers of Personalized Medicine
inferred← citeshttps://doi.org/10.1159/000464100openalex-snapshot
Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements
inferred← citeshttps://doi.org/10.1159/000509272openalex-snapshot
Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU’s Orphan Regulation? And if so, What Should be Changed?
inferred← citeshttps://doi.org/10.1177/1091581816644709openalex-snapshot
Workshop Proceedings
inferred← citeshttps://doi.org/10.1182/asheducation-2013.1.19openalex-snapshot
Drug discovery in rare indications: opportunities and challenges
inferred← citeshttps://doi.org/10.1185/03007995.2012.673480openalex-snapshot
Retrospective outcomes studies for orphan diseases: challenges and opportunities
inferred← citeshttps://doi.org/10.1186/1750-1172-6-42openalex-snapshot
Pricing and reimbursement of orphan drugs: the need for more transparency
inferred← citeshttps://doi.org/10.1186/1750-1172-6-59openalex-snapshot
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
inferred← citeshttps://doi.org/10.1186/1750-1172-6-62openalex-snapshot
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
inferred← citeshttps://doi.org/10.1186/1750-1172-8-109openalex-snapshot
Sustainable rare diseases business and drug access: no time for misconceptions
inferred← citeshttps://doi.org/10.1186/1750-1172-8-157openalex-snapshot
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
inferred← citeshttps://doi.org/10.1186/1750-1172-8-164openalex-snapshot
Clinical evidence for orphan medicinal products-a cause for concern?
inferred← citeshttps://doi.org/10.1186/1758-2946-6-5openalex-snapshot
The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation
inferred← citeshttps://doi.org/10.1186/gm326openalex-snapshot
Drug repositioning for personalized medicine
inferred← citeshttps://doi.org/10.1186/s13023-014-0170-0openalex-snapshot
A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov
inferred← citeshttps://doi.org/10.1186/s13023-015-0241-xopenalex-snapshot
A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
inferred← citeshttps://doi.org/10.1186/s13023-015-0269-yopenalex-snapshot
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
inferred← citeshttps://doi.org/10.1186/s13023-016-0455-6openalex-snapshot
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
inferred← citeshttps://doi.org/10.1186/s13023-017-0578-4openalex-snapshot
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
inferred← citeshttps://doi.org/10.1186/s13023-017-0614-4openalex-snapshot
Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery
inferred← citeshttps://doi.org/10.1186/s13023-017-0617-1openalex-snapshot
Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
inferred← citeshttps://doi.org/10.1186/s13023-018-0930-3openalex-snapshot
Investigating the landscape of US orphan product approvals
inferred← citeshttps://doi.org/10.1186/s13023-018-0990-4openalex-snapshot
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
inferred← citeshttps://doi.org/10.1186/s13023-020-01624-0openalex-snapshot
Stakeholder perspectives on clinical research related to therapies for rare diseases: therapeutic misconception and the value of research
inferred← citeshttps://doi.org/10.1186/s13023-021-01925-yopenalex-snapshot
A systematic review of moral reasons on orphan drug reimbursement
inferred← citeshttps://doi.org/10.1186/s13023-023-02987-wopenalex-snapshot
Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.1186/s13023-025-04132-1openalex-snapshot
How social pharmaceutical innovations are addressing problems of availability, accessibility and affordability of drugs for rare diseases
inferred← citeshttps://doi.org/10.1186/s13023-026-04367-6openalex-snapshot
Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study
inferred← citeshttps://doi.org/10.1186/s13104-026-07990-5openalex-snapshot
TheRareLens: a quantitative framework for identifying research funding disparities in rare and autoimmune diseases relative to patient burden
inferred← citeshttps://doi.org/10.1186/s40064-016-2323-1openalex-snapshot
Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry
inferred← citeshttps://doi.org/10.1186/s42358-024-00407-6openalex-snapshot
Rare diseases: What rheumatologists need to know?
inferred← citeshttps://doi.org/10.1212/wnl.0b013e3182661eb1openalex-snapshot
Tafamidis for transthyretin familial amyloid polyneuropathy
inferred← citeshttps://doi.org/10.12688/f1000research.130388.1openalex-snapshot
Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan
inferred← citeshttps://doi.org/10.12688/f1000research.130388.2openalex-snapshot
Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan
inferred← citeshttps://doi.org/10.12688/f1000research.130809.1openalex-snapshot
Pharmaceutical policy and innovation for rare diseases: A narrative review
inferred← citeshttps://doi.org/10.12688/f1000research.130809.2openalex-snapshot
Pharmaceutical policy and innovation for rare diseases: A narrative review
inferred← citeshttps://doi.org/10.12795/araucaria.2021.i46.21openalex-snapshot
Enfermedades priónicas: historia, diversidad e importancia socioeconómica como paradigma de las Enfermedades Raras
inferred← citeshttps://doi.org/10.1371/journal.pmed.1002966openalex-snapshot
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
inferred← citeshttps://doi.org/10.1371/journal.pone.0140002openalex-snapshot
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
inferred← citeshttps://doi.org/10.1371/journal.pone.0164681openalex-snapshot
Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study
inferred← citeshttps://doi.org/10.1377/hlthaff.2012.0235openalex-snapshot
Proposed ‘Grant-And-Access’ Program With Price Caps Could Stimulate Development Of Drugs For Very Rare Diseases
inferred← citeshttps://doi.org/10.1517/21678707.2013.769876openalex-snapshot
Orphan drug designation – Europe, the USA and Japan
inferred← citeshttps://doi.org/10.1517/21678707.2014.885833openalex-snapshot
Evaluation of galsulfase for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
inferred← citeshttps://doi.org/10.1533/9781908818393.247openalex-snapshot
Market access procedures for orphan drugs
inferred← citeshttps://doi.org/10.1542/peds.2011-1798openalex-snapshot
What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
inferred← citeshttps://doi.org/10.1553/ita-pacita-06openalex-snapshot
PACITA: Expert Working Group report for the European Future Panel on Public Health Genomics (January 2014)
inferred← citeshttps://doi.org/10.15586/codon.pkd.2015.ch6openalex-snapshot
Clinical Trials in Autosomal Dominant Polycystic Kidney Disease
inferred← citeshttps://doi.org/10.1586/14737167.2015.965156openalex-snapshot
Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
inferred← citeshttps://doi.org/10.1634/theoncologist.2015-0397openalex-snapshot
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis
inferred← citeshttps://doi.org/10.20381/ruor-4352openalex-snapshot
Consideration for Rare Diseases in the Context of Drug Reimbursement Processes
inferred← citeshttps://doi.org/10.20517/rdodj.2023.29openalex-snapshot
2017-2023: state of the art of gene therapies in rare diseases in Europe: the dynamics of clinical R&D, new approved treatments and expected therapies in the pipelines
inferred← citeshttps://doi.org/10.2146/ajhp130348openalex-snapshot
Health disparities: Exploring the ethics of orphan drugs
inferred← citeshttps://doi.org/10.2147/dddt.s46289openalex-snapshot
Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases
inferred← citeshttps://doi.org/10.2147/odrr.s33085openalex-snapshot
Do ultra-orphan medicinal products warrant ultra-high prices? A review
inferred← citeshttps://doi.org/10.2165/11635320-000000000-00000openalex-snapshot
Orphan Drugs for Rare Diseases
inferred← citeshttps://doi.org/10.2174/0929867328666210526144654openalex-snapshot
Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency
inferred← citeshttps://doi.org/10.2196/16734openalex-snapshot
Ethical, Legal, and Social Issues Related to the Inclusion of Individuals With Intellectual Disabilities in Electronic Health Record Research: Scoping Review
inferred← citeshttps://doi.org/10.2217/cer.14.34openalex-snapshot
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
inferred← citeshttps://doi.org/10.2217/ebo.12.314openalex-snapshot
Challenges for the regulatory agencies in establishing an environment favorable for stratified medicine
inferred← citeshttps://doi.org/10.2745/dds.26.118openalex-snapshot
Venture activities
inferred← citeshttps://doi.org/10.31688/abmu.2019.54.1.23openalex-snapshot
Physician-patient relationship in rare diseases: an ethical approach
inferred← citeshttps://doi.org/10.33140/jpr.08.02.05openalex-snapshot
Recent Advances in Regulatory Science for Pharmaceutical Development and Approval
inferred← citeshttps://doi.org/10.33380/2305-2066-2023-12-2-198-205openalex-snapshot
Regulation of the Launch of Orphan Drugs on the Market of the Eurasian Economic Union as a Mechanism to Increase the Availability of Treatment for Rare Diseases (Review)
inferred← citeshttps://doi.org/10.33612/diss.206096858openalex-snapshot
Multi-criteria Decision Analysis for Assessing Orphan Drugs
inferred← citeshttps://doi.org/10.3389/fmed.2022.832662openalex-snapshot
The Research Landscape of Multiple Endocrine Neoplasia Type 1 (2000–2021): A Bibliometric Analysis
inferred← citeshttps://doi.org/10.3389/fped.2020.00079openalex-snapshot
Experience With Pediatric Medical Device Development
inferred← citeshttps://doi.org/10.3389/fphar.2024.1298923openalex-snapshot
Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review
inferred← citeshttps://doi.org/10.3390/healthcare10091600openalex-snapshot
Making Sure That Orphan Incentives Tip the Right Way in Europe
inferred← citeshttps://doi.org/10.3390/ijerph19106057openalex-snapshot
Rare Diseases in the Educational Field: Knowledge and Perceptions of Spanish Teachers
inferred← citeshttps://doi.org/10.3390/su11051289openalex-snapshot
From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue
inferred← citeshttps://doi.org/10.38212/2224-6614.3383openalex-snapshot
The impact of The Rare Disease and Orphan Drug Act in Taiwan
inferred← citeshttps://doi.org/10.3917/jgem.154.0221openalex-snapshot
La désignation européenne de « médicament orphelin » : un déterminant du prix des médicaments pour maladies rares ?
inferred← citeshttps://doi.org/10.3989/arbor.2018.789n3008openalex-snapshot
Medicamentos huérfanos
inferred← citeshttps://doi.org/10.4103/ijp.ijp_979_25openalex-snapshot
Orphan drugs: The final frontier in the fight against rare diseases
inferred← citeshttps://doi.org/10.4415/ann_11_01_17openalex-snapshot
Rare diseases and orphan drugs.
inferred← citeshttps://doi.org/10.48121/jihsam.874683openalex-snapshot
Examining of Health Policy in Rare Diseases in Terms of Historical Perspective in Turkey
inferred← citeshttps://doi.org/10.5135/eusj.2014.270openalex-snapshot
The Effect of Financial Pressure on Innovation in EU Strategies on Orphan Drugs
inferred← citeshttps://doi.org/10.5463/thesis.499openalex-snapshot
Managing University-Industry Collaborative Innovation in the Pharmaceutical Industry
inferred← citeshttps://doi.org/10.5582/irdr.2012.v1.1.1openalex-snapshot
Intractable and rare diseases research
inferred← citeshttps://doi.org/10.5582/irdr.2012.v1.1.3openalex-snapshot
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives
inferred← citeshttps://doi.org/10.5582/irdr.2012.v1.2.95openalex-snapshot
New opportunity for orphan drug development in Japan: Early exploratory clinical trial bases promote drug translation from basic studies to clinical application
inferred← citeshttps://doi.org/10.5633/amm.2013.0204openalex-snapshot
EVALUATION OF PHARMACISTS’ KNOWLEDGE AND ATTITUDES REGARDING RARE DISEASES AND ORPHAN DRUGS
inferred← citeshttps://doi.org/10.5694/mja2.70094openalex-snapshot
The CURE Asthma roadmap
inferred← citeshttps://doi.org/10.5772/28094openalex-snapshot
Recent Advances in Biotherapeutics Drug Discovery and Development
inferred← citeshttps://doi.org/10.5897/err2017.3186openalex-snapshot
A systematic review of research into rare diseases in the educational sphere
inferred← citeshttps://doi.org/10.5937/pravzap0-20657openalex-snapshot
Availability of Orphan drugs: Basic legal issues of development and financing
inferred← citeshttps://doi.org/10.6084/m9.figshare.14889174openalex-snapshot
Additional file 1 of A systematic review of moral reasons on orphan drug reimbursement
inferred← citeshttps://doi.org/10.6084/m9.figshare.14889177openalex-snapshot
Additional file 2 of A systematic review of moral reasons on orphan drug reimbursement
inferred← citeshttps://doi.org/10.6084/m9.figshare.14889180openalex-snapshot
Additional file 3 of A systematic review of moral reasons on orphan drug reimbursement
inferred← citeshttps://doi.org/10.6084/m9.figshare.14889186openalex-snapshot
Additional file 5 of A systematic review of moral reasons on orphan drug reimbursement
inferred← citeshttps://doi.org/10.6084/m9.figshare.26647863openalex-snapshot
Additional file 1 of Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26647866openalex-snapshot
Additional file 2 of Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26647869openalex-snapshot
Additional file 3 of Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26647872openalex-snapshot
Additional file 4 of Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26647875openalex-snapshot
Additional file 5 of Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26647878openalex-snapshot
Additional file 6 of Qualified placebo for trials of herbal medicine treatment in rare diseases? A cross-sectional analysis
inferred← citeshttps://doi.org/10.70675/5c1571dcz0550z4a38z8897z09e7933d2e9dopenalex-snapshot
Les médicaments orphelins dans l'Union européenne : la maintenance de la désignation orpheline
inferred← citeshttps://doi.org/10.7324/japs.2018.8822openalex-snapshot
Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases
inferred← citeshttps://doi.org/10.7365/jhpor.2019.2.5openalex-snapshot
Ethical, economic and clinical aspects of financing treatment of rare diseases
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.